Day Trading Goal
  • Investing
  • Economy
  • Editor’s Pick
  • Latest News
  • Investing
  • Economy
  • Editor’s Pick
  • Latest News
No Result
View All Result
Day Trading Goal
No Result
View All Result
Home Latest News

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

admin by admin
October 3, 2025
in Latest News
0
Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS

Previous Post

Federal judge to sentence Justice Brett Kavanaugh’s attempted assassin

Next Post

Trump’s DOGE savings dwarfed by Medicare, Social Security spending, watchdog finds

Next Post
Trump’s DOGE savings dwarfed by Medicare, Social Security spending, watchdog finds

Trump’s DOGE savings dwarfed by Medicare, Social Security spending, watchdog finds

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • Trending
    • Comments
    • Latest
    Thatcher at 100: Lessons in civility, strength and enduring alliances

    Thatcher at 100: Lessons in civility, strength and enduring alliances

    October 13, 2025
    ASML share price forecast after earnings: buy or sell?

    ASML share price forecast after earnings: buy or sell?

    October 15, 2025
    Trump ally Ben Carson sworn in as national advisor for nutrition, health, and housing with USDA

    Trump ally Ben Carson sworn in as national advisor for nutrition, health, and housing with USDA

    September 25, 2025
    Top crypto price predictions: Avantis, Lista DAO, Aevo

    Top crypto price predictions: Avantis, Lista DAO, Aevo

    September 21, 2025
    From $14B to near zero: is Beyond Meat stock worth buying now?

    From $14B to near zero: is Beyond Meat stock worth buying now?

    0
    WATCH: Defiant Kash Patel says he’s ‘proud’ to lead FBI after explosive hearing

    WATCH: Defiant Kash Patel says he’s ‘proud’ to lead FBI after explosive hearing

    0
    How AI browsers open the door to new scams

    How AI browsers open the door to new scams

    0
    Trump caps UK trip with $350B tech pact, heads to Arizona for Kirk’s memorial service

    Trump caps UK trip with $350B tech pact, heads to Arizona for Kirk’s memorial service

    0
    From $14B to near zero: is Beyond Meat stock worth buying now?

    From $14B to near zero: is Beyond Meat stock worth buying now?

    October 21, 2025
    Here’s why the blue-chip Hang Seng Index is rising today

    Here’s why the blue-chip Hang Seng Index is rising today

    October 21, 2025
    Nifty 50 Index forecast as Indian earnings season continues

    Nifty 50 Index forecast as Indian earnings season continues

    October 21, 2025
    Yes Bank share price golden cross points to a rebound after earnings

    Yes Bank share price golden cross points to a rebound after earnings

    October 21, 2025

    Recent News

    From $14B to near zero: is Beyond Meat stock worth buying now?

    From $14B to near zero: is Beyond Meat stock worth buying now?

    October 21, 2025
    Here’s why the blue-chip Hang Seng Index is rising today

    Here’s why the blue-chip Hang Seng Index is rising today

    October 21, 2025
    Nifty 50 Index forecast as Indian earnings season continues

    Nifty 50 Index forecast as Indian earnings season continues

    October 21, 2025
    Yes Bank share price golden cross points to a rebound after earnings

    Yes Bank share price golden cross points to a rebound after earnings

    October 21, 2025

    Popular News

    From $14B to near zero: is Beyond Meat stock worth buying now?

    From $14B to near zero: is Beyond Meat stock worth buying now?

    October 21, 2025
    Here’s why the blue-chip Hang Seng Index is rising today

    Here’s why the blue-chip Hang Seng Index is rising today

    October 21, 2025

    Latest News

    • From $14B to near zero: is Beyond Meat stock worth buying now?
    • Here’s why the blue-chip Hang Seng Index is rising today
    • Nifty 50 Index forecast as Indian earnings season continues
    • Yes Bank share price golden cross points to a rebound after earnings

    About DayTradingGoal

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 Daytradinggoal.com All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Economy
    • Editor’s Pick
    • Latest News

    Copyright © 2025 Daytradinggoal.com All Rights Reserved.